CARDIFF ONCOLOGY
Cardiff Oncology is a clinical-stage oncology therapeutics company developing drugs that target cell division for the treatment of leukemias, lymphomas, and solid tumor cancers. It has a broad intellectual property and proprietary technology to measure circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies. The company offers its PCM technology at its CLIA/CAP-accredited laboratory and plans to continue to vertically integrate its PCM technology with precision cancer therapeutics. Cardiff Oncology (formerly known as Trovagene) was founded in 1999 and is headquartered in San Diego, California.
CARDIFF ONCOLOGY
Industry:
Biotechnology Health Care Health Diagnostics Medical
Founded:
1999-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.cardiffoncology.com
Total Employee:
11+
Status:
Active
Contact:
+1 858-952-7570
Email Addresses:
[email protected]
Total Funding:
80.46 M USD
Technology used in webpage:
SPF Google Font API Mobile Non Scaleable Content Microsoft Exchange Online Office 365 Mail IPv6 Google Maps GoDaddy DNS Google PHP 7
Similar Organizations
ABT Molecular Imaging
ABT Molecular Imaging develops a production platform to generate unit doses of molecular imaging drugs for PET scanning at the point of use.
ADMA Biologics
ADMA Biologics develops plasma-based biologics for the treatment and prevention of certain infectious diseases.
Apollo Hospitals Enterprise
Apollo Hospitals is a premium multi-specialty hospital of India and is one of the largest integrated healthcare groups.
Atonarp
Atonarp combines electronics and data processing algorithms for chemical composition analysis.
Tarveda Therapeutics
Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors.
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
CellPhire
Cellphire has developed a proprietary method for the stabilization of blood in the dry state
CVRx
CVRx is a medical device company developing implantable technology for the treatment of high blood pressure.
Edison Pharmaceuticals
Edison Pharmaceuticals develops medicines for the treatments of children and adults diagnosed with rare and neglected diseases.
Vero Biotech
Vero Biotech is a biopharmaceutical company that commercializes inhaled nitric oxide delivery systems for healthcare providers.
GluMetrics
GluMetrics, a medical company based in Irvine, California, develops tools that enable clinicians to implement a care paradigm for patients.
Kipu Health
SaaS platform for behavioral health and addiction treatment centers providing EHR, patient engagement and RCM solutions.
NanoString Technologies
NanoString Technologies provides a life science tools platform for a variety of basic research, translational medicine and IVD applications.
NeoGenomics
NeoGenomics is a cancer reference laboratory that provides cancer testing and partnership programs to pathologists and oncologists.
Knopp Biosciences
Knopp Neurosciences is a drug discovery and development company working on treatments for neurological disorders.
Omega Diagnostics
Omega Diagnostics provides IVD products for use in hospitals, blood banks, clinics, and laboratories.
Sunshine Biopharma
Sunshine Biopharma focuses on the research, development, and commercialization of drugs for the treatment of various forms of cancer.
Thyrocare Technologies
Thyrocare Technologies Limited is India's first fully automated diagnostic laboratory.
Current Employees Featured
Founder
Stock Details
Investors List
Pfizer Breakthrough Growth Initiative
Pfizer Breakthrough Growth Initiative investment in Post-IPO Equity - Cardiff Oncology
Acorn Bioventures
Acorn Bioventures investment in Post-IPO Equity - Cardiff Oncology
CAM Capital
CAM Capital investment in Post-IPO Equity - Cardiff Oncology
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Debt - Cardiff Oncology
Silicon Valley Bank
Silicon Valley Bank investment in Post-IPO Debt - Cardiff Oncology
Key Employee Changes
Official Site Inspections
http://www.cardiffoncology.com Semrush global rank: 4.11 M Semrush visits lastest month: 2.94 K
- Host name: 104.22.30.226
- IP address: 104.22.30.226
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Cardiff Oncology"
About - Cardiff Oncology
About Leadership Press releases Media Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel …See details»
Management Team - Cardiff Oncology
By combining our collective oncology drug development and biomarker technology expertise with decades of experience, we are turning the tide on cancer.See details»
Board of Directors - Cardiff Oncology, Inc.
Prior to her role at Elan, Dr. Tannenbaum spent three years leading the global commercial operations organization at Novartis Pharma AG, and nine and sixteen years at Bristol Myers …See details»
Cardiff Oncology - LinkedIn
Cardiff Oncology Biotechnology Research San Diego, California 4,544 followers Cardiff Oncology is a clinical-stage company with the mission of developing new treatment options for cancer patients.See details»
Cardiff Oncology Company Profile | Management and Employees …
Cardiff Oncology Profile and History Cardiff Oncology is a clinical-stage company with the singular mission of developing new treatment options for cancer patients. Our goal is to overcome …See details»
Cardiff Oncology to Report First Quarter 2024 Results and Provide ...
These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit …See details»
Cardiff Oncology - PitchBook
Information on stock, financials, earnings, subsidiaries, investors, and executives for Cardiff Oncology. Use the PitchBook Platform to explore the full profile.See details»
Cardiff Oncology - Craft
Oct 29, 2024 Cardiff Oncology is a biotech company. The company develops therapies and treatments for solid tumor and hematologic cancers. It provides onvansertib, a Polo-like …See details»
Cardiff Oncology - Overview, News & Similar companies
May 13, 2024 View Cardiff Oncology (www.cardiffoncology.com) location in California, United States , revenue, industry and description. Find related and similar companies as well as …See details»
Cardiff Oncology - Research - Overview, Competitors, and
Cardiff Oncology information Cardiff Oncology is a clinical-stage biotechnology company, headquartered in San Diego, CA, leveraging PLK1 inhibition, a well-validated oncology drug …See details»
Release Details - Cardiff Oncology, Inc.
Feb 29, 2024 These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior …See details»
Board of Directors - Cardiff Oncology
We are benefiting from the expertise of veteran pharmaceutical and biotech executives to align our current and future growth and success strategy.See details»
Cardiff Oncology Company Overview, Contact Details
Learn more about Cardiff Oncology's company details, contact information, competitors, and more. Find accurate contact data easily with LeadIQ. Book a demo today.See details»
Cardiff Oncology Reports Third Quarter 2023 Results and Provides ...
Sep 30, 2023 Cardiff Oncology will host a corresponding conference call and live webcast at 4:30 p.m. ET / 1:30 p.m. PT on November 2, 2023. Individuals interested in listening to the live …See details»
Turning the Tide on Cancer - Cardiff Oncology
Forward-Looking Statements Certain statements in this presentation are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be …See details»
Cardiff Oncology Announces New Lead Program in First-Line …
SAN DIEGO, August 7, 2023. Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to …See details»
Cardiff Oncology Announces Upcoming Presentations at the AACR …
Mar 10, 2021 The full texts of the published abstracts are currently available on the AACR Annual Meeting 2021 website. The corresponding posters will be available for on-demand …See details»
Cardiff Oncology announces positive colorectal data and $40m …
3 days ago Cardiff Oncology plans to share additional clinical data from its onvansertib trial in the first half of 2025.See details»
Release Details - Cardiff Oncology, Inc.
Jul 12, 2021 A Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia (AML) completed enrollment in 2020. For more information, …See details»
Cardiff Oncology Prices Oversubscribed $40 Million Underwritten ...
Direct Ofering SAN DIEGO, December 10, 2024 – Cardiff Oncology, Inc. (Nasdaq: CRDF) (“Cardiff Oncology” or the “Company”), a clinical-stage biotechnology company leveraging …See details»